A concurrent parallel study to compare the efficacy and safety of oral iron chelators, defrasirox and defriprone in patients of beta thalassaemia major

Simple item page
dc.contributor.authorGupta, Pankajen_US
dc.contributor.authorGupta, Mamtaen_US
dc.contributor.authorNyati, Premen_US
dc.contributor.authorRaipurkar, Swati P.en_US
dc.contributor.authorTripathi, Surajen_US
dc.contributor.authorThora, Sharaden_US
dc.date.accessioned2020-04-23T07:49:35Z
dc.date.available2020-04-23T07:49:35Z
dc.date.issued2018-05
dc.description.abstractBackground: This study was planned to evaluate all the cases of ? thalassaemia major, already receiving one of the oral iron chelators for a comparison among the efficacy, safety and economy of deferasirox and deferiprone to establish the better option in an Indian scenario.Methods: We identified two groups of patients: 38 treated with deferasirox and 35 treated with deferiprone. Laboratory parameters such as serum ferritin, creatinine, SGPT, Hb, CBC and urine were recorded at the time of inclusion and at 1, 3 and 6 months after the inclusion. The primary outcome variable was serum Ferritin level at the start and at the end of study. Serum ferritin level was carried out by microparticle enzyme linked immunoassay.Results: Before the study, the mean hemoglobin level was 7.32±1.50mg/dL ranged from 4 to 10.8 in deferasirox group and 7.54±1.15mg/dL ranged from 5.5 to 8.8 in deferiprone group. At the time of inclusion, study population was characterized by a mean serum ferritin value of 4735.11±450.01 SE in deferasirox and 4315.97±340.75 SE in deferiprone group. After one month the mean serum ferritin increases to 4578.66±371.96 in deferasirox and 4388.82±316.16 in deferiprone group. After three month the mean serum ferritin reduces to 4295.60±377.37 in deferasirox and 3988.88±349.84 in Deferiprone group.Conclusions: Thus, we conclude that deferasirox and deferiprone are well tolerated, have few adverse effects and almost have a comparable effect in lowering of the patient's serum ferritin level. Deferiprone is more cost effective but needs a strict control on compliance owing to requirement in three divided doses per day.en_US
dc.identifier.affiliationsDepartment of Radiodiagnosis, Index Medical College Hospital & Research Centre, Index City, Nemawar Road, NH-59A, Indore, Madhya Pradesh 452016, Indiaen_US
dc.identifier.affiliationsDepartment of Pathology, Amaltas Institute of Medical Sciences, Village Bangar, DewasUjjain Highway, Dewas, Madhya Pradesh 455001, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, Index Medical College Hospital & Research Centre, Index City, Nemawar Road, NH-59A, Indore, Madhya Pradesh 452016, Indiaen_US
dc.identifier.affiliationsDepartment of Paediatrics, Index Medical College Hospital & Research Centre, Index City, Nemawar Road, NH-59A, Indore, Madhya Pradesh 452016, Indiaen_US
dc.identifier.affiliationsDepartment of Paediatrics, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh 452001, Indiaen_US
dc.identifier.citationGupta Pankaj, Gupta Mamta, Nyati Prem, Raipurkar Swati P., Tripathi Suraj, Thora Sharad. A concurrent parallel study to compare the efficacy and safety of oral iron chelators, defrasirox and defriprone in patients of beta thalassaemia major. International Journal of Basic & Clinical Pharmacology. 2018 May; 7(5): 1028-1035en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/199701
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber5en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20181656en_US
dc.subjectBeta thalassaemia majoren_US
dc.subjectDefrasiroxen_US
dc.subjectDefriproneen_US
dc.subjectEfficacyen_US
dc.subjectOral iron chelatorsen_US
dc.subjectSafetyen_US
dc.titleA concurrent parallel study to compare the efficacy and safety of oral iron chelators, defrasirox and defriprone in patients of beta thalassaemia majoren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2018v7n5p1028.pdf
Size:
258.34 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology